On this episode of Talk Radioisotopes, hosts Scott Larrivee and Sarah Scouten interview Arjun Murthy, co-founder of Maven Bio, an AI-driven biopharma market intelligence platform.
They explore how Arjun’s background, along with Maven Bio’s technology, is transforming data analysis and research in the biopharma sector. Key topics include how AI is aiding radiopharmaceutical research, the importance of robust supply chains, and potential future developments in cancer treatment. Arjun shares insights on the role of AI in competitive intelligence, market research, and product planning within the complex biopharma industry.
Time Stamps:
- *(02:04) What Can Consultants and Platforms Add to the Conversation?
- *(06:06) AI: A Synthesis of Intelligence
- *(13:34) Maven Bio’s Start with Y Combinator
- *(16:34) Digging into Radiopharmaceutical Data
- *(20:35) M&A and Supply Chain in 2025
- *(25:22) The Next Five Years in Radiopharma
Talk Radioisotopes: Going Nuclear on Cancer is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.
Links:
